News

There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…

AbstractSystemic amyloid light-chain (AL) amyloidosis is a multisystem disorder caused by extracellular deposition of monoclonal immunoglobulin light chains.…

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…

AbstractBackgroundPathogenic transthyretin (TTR) variants, such as V142I, demonstrate incomplete, age-dependent penetrance and may be present in patients without…

AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…

Prothena Biosciences announced that coramitug (previously PRX004) has received Fast Track designation for the treatment of transthyretin amyloid cardiomyopathy…

Older patients hospitalized due to heart failure in the US were cared for with frequent outpatient clinic visits before and after heart failure hospitalization,…

TOPLINE:In patients newly diagnosed with cardiac amyloidosis (CA), continuous rhythm monitoring using implantable loop recorders found that clinically significant…

Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene…

AbstractBackground and Purpose: Transthyretin (ATTR) amyloidosis, including wild-type (ATTRwt) and hereditary (ATTRv) forms, is a rare but increasingly recognized…